Veille Scientifique

Patrice PIENKOWSKI
Coordinateur

 Après 3 ans de bons et loyaux services, la veille scientifique va s’arrêter ; voici les derniers articles sélectionnés à votre intention.
 
Nous avons pris cette décision difficile suite au constat d’un investissement très important pour un service rendu finalement incertain, comme l’attestent les statistiques de fréquentation de la rubrique sur ce site. 
 
Je remercie tous ceux et celles qui se sont investis dans la durée pour assurer la réussite du projet, à commencer par les responsables des groupes de veille : Emmanuel Coron (Endoscopie), Roger Faroux (Cancérologie), Pauline Jouët (Gastro-entérologie et proctologie), Stéphane Nahon (MICI), Vinciane Rebours (Pancréatologoie) et Christine Silvain (Hépatologie), mais aussi et surtout, tous les veilleurs anonymes pour la grande qualité de leur travail, leur compétence et leur persévérance.
Le travail de veille bibliographique ne disparait pas complètement malgré tout, grâce aux GastroScoops dont la fréquence va augmenter avec un objectif de diffusion hebdomadaire ; il s’agit d’un travail rédactionnel différent avec une analyse d’article plus approfondie et structurée, porteur de message important.

Restez donc fidèles à ces rubriques et visitez régulièrement le site de la SNFGE toujours très riche d’enseignements et d’informations.

Très cordialement.

Dr Patrice PIENKOWSKI

 

Six groupes animés par un responsable se chargent de ce travail tous les mois :

Cancers Endoscopie

Foie/
VB/
Addicto

Gastro/
Procto/

Nutrition
MICI Pancréas
A. LIEVRE V. VALANTIN I. ROSA P. JOUET S. NAHON V. REBOURS

V. HAUTEFEUILLE
N. WILLIET
N. FARES
Y. TOUCHEFEU

A. CULETTO
Y. LEBALEUR
G. PERROD
V. VALANTIN

C. BARRAULT
P. DUKAN
N. GANNE-CARRIE
PE. RAUTOU

H. DAMON
T. HIGUERO
V. de PARADES
F. ZERBIB

V. ABITBOL
P. FAURE
M. FUMERY
D LAHARIE
P. SEKSIK

M. CAMUS-DUBOC
E. GELSI
L. de MESTIER


Nous espérons de ce nouvel outil qu’il vous aide à accéder rapidement et sélectivement aux données nouvelles de notre discipline selon vos sujets d’intérêt, qu’ils soient larges ou très spécifiques.

Revuetrier par ordre croissant Titre Date Coup de coeur Thématique
Clinical Gastroenterology and Hepatology Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission fév. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology No Association Between Consumption of Sweetened Beverages and Risk of Later-Onset Crohn's Disease or Ulcerative Colitis. Jan. 19 3 ♥ MICI
Clinical Gastroenterology and Hepatology Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. mar. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab. aoû. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology Features of Patients With Crohn's Disease and Hidradenitis Suppurativa. Jan. 16 3 ♥ MICI
Clinical Gastroenterology and Hepatology Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months. nov. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010 juin. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study aoû. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide sep. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases Jan. 19 3 ♥ MICI
Clinical Gastroenterology and Hepatology Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity. nov. 17 4 ♥ MICI
Clinical Gastroenterology and Hepatology Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders. déc. 17 4 ♥ Coloproctologie
Inflammatory Bowel Diseases Capsule Endoscopy: Diagnostic Accuracy of Lewis Score in Patients with Suspected Crohn's Disease oct. 15 2 ♥ MICI
Inflammatory Bowel Diseases Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn's Disease Treated with Biologics with or Without Previous Seton Placement. oct. 17 4 ♥ Coloproctologie
Inflammatory Bowel Diseases Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease juil. 17 3 ♥ MICI
Inflammatory Bowel Diseases Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn’s Disease aoû. 17 3 ♥ MICI
Inflammatory Bowel Diseases Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. mai. 16 4 ♥ MICI
Inflammatory Bowel Diseases The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure avr. 17 2 ♥ MICI
Inflammatory Bowel Diseases Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study avr. 17 2 ♥ MICI
Inflammatory Bowel Diseases Frequency and Risk Factors of Clostridium difficile Infection in Hospitalized Patients With Pouchitis: A Population-based Study Gaurav avr. 17 3 ♥ MICI
Inflammatory Bowel Diseases Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Jan. 17 2 ♥ MICI
Inflammatory Bowel Diseases The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. fév. 17 2 ♥ MICI
Inflammatory Bowel Diseases The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease juin. 17 3 ♥ MICI
Inflammatory Bowel Diseases 2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial mai. 17 2 ♥ MICI
Inflammatory Bowel Diseases Preoperative Use of Methotrexate and the Risk of Early Postoperative Complications in Patients with Inflammatory Bowel Disease aoû. 16 3 ♥ Intestin/Nutrition/Troubles fonctionnels

Pages